Company Overview
Company Type: Public Company
Website: www.gud-knight.com
Number of Employees: 698
Ticker: GUD (TSX)
Year Founded: 2013


Business Description
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
326.4
Market Capitalization
492.6
TEV/Total Revenue
1.3x
EBITDA
42.6
Total Enterprise Value
414.4
TEV/EBITDA
8.9x
EBIT
(13.6)
Cash & ST Invst.
150.0
P/Diluted EPS Before Extra
NM
Net Income
(15.7)
Total Debt
79.2
Price/Tang BV
1.2x
Capital Expenditure
(3.1)
Total Assets
1,013.7
Total Debt/EBITDA
1.7x
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-10-2023


Estimates & Guidance Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Guidance Current FQ
Current FY
Guidance Current FY
NTM
EPS (GAAP)
(0.04)
-
(0.08)
-
(0.06)
Revenue (mm)
73.51
-
322.05
310.00 - 330.00
302.88
EBITDA (mm)
10.43
-
53.91
49.60 - 56.10
43.00

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/REV
1.29x
TEV/EBITDA
7.69x
P/BV
0.64x

Non-Periodic Estimates

Recommendation
Outperform (2.00)
Target Price
6.20
Potential Upside
35.08%


Key Professionals
Name
Title
Goodman, Jonathan Ross
Executive Chairman
Sakhia, Samira 
President, CEO & Director
Utchanah, Arvind 
Chief Financial Officer
Bosano, Leopoldo 
Vice-President of Manufacturing & Operations
Percario, Monica 
Global Vice President of Scientific Affairs
Dias, Henrique 
Global Director of Marketing
Emblem, Susan Caroline
Global Vice President of Human Resources
Khouri, Amal 
Chief Business Officer
Martens, Jeff 
Global Vice President of Commercial
Saverio, Stephani 
Vice President of Business Development

Key Board Members
Name
Title
Goodman, Jonathan Ross
Executive Chairman
Sakhia, Samira 
President, CEO & Director
Lande, Robert N.
Independent Director
Tremblay, Michael J.
Independent Director
Gale, James Charles
Independent Lead Director
Murray, Janice 
Independent Director
Sujoy, Nicolas 
Independent Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
3400 de Maisonneuve Boulevard West Suite 1055 | Montreal, QC | H3Z 3B8 | Canada
Phone: 514-484-4483   Fax: 514-481-4116

Current and Pending Investors
Fondaction, Long Zone Holdings Inc., Medison Biotech Ltd.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 4.59
Market Cap (mm)
488.4
Open
 4.61
Shares Out. (mm)
106.4
Previous Close
 4.59
Float %
55.8%
Change on Day
(0.04)
Shares Sold Short (mm)
-
Change % on Day
(0.9)%
Dividend Yield %
-
Day High/Low
 4.66/ 4.56
Diluted EPS Excl. Extra Items
(0.14)
52 wk High/Low
 5.60/ 4.28
P/Diluted EPS Before Extra
NM
Volume (mm)
0.04
Avg 3M Dly Vlm (mm)
0.06
Beta 5Y
0.47


 
Delayed Quote** | Last Updated on Oct-11-2023 12:00 AM (GMT-5)
TSX:GUD - Common Stock


Index Membership
S&P/TSX SmallCap Index;S&P Americas Under USD3 Billion Index;S&P Americas BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas Under USD2 Billion Index;S&P Americas BMI Growth Index;S&P Americas SmallCap Health Care (Sector) Index;S&P Americas Under USD1 Billion Index;S&P Canada SmallCap Index;S&P Canada SmallCap Growth Index;S&P Canada SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas BMI Index;S&P Americas BMI Health Care (Sector) Index;S&P Americas SmallCap Index;S&P Developed BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas Under USD1.2 Billion Index;S&P Canada BMI Growth Index;S&P Americas SmallCap Growth Index;S&P Americas Under USD1.5 Billion Index;S&P Canada Under USD2 Billion Index;S&P Americas SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P DM Ex-Australia SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Canada SmallCap Health Care (Sector) Index;S&P Canada Under USD3 Billion Index;S&P Canada BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific BMI Growth Health Care (Sector) Index;S&P Developed Ex-Australia Under USD1 Billion Index;S&P Developed Ex-Australia Under USD1.2 Billion Index;S&P Developed Ex-Europe BMI Growth Index;S&P Developed Ex-Europe BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe SmallCap Health Care (Sector) Index;S&P Developed BMI Index;S&P Developed Ex-Asia-Pacific BMI Growth Index;S&P Developed Ex-Australia BMI Index;S&P Developed Ex-Eurozone BMI Growth Index;S&P Developed Ex-Eurozone SmallCap Index;S&P Developed Ex-Eurozone SmallCap Health Care (Sector) Index;S&P Developed BMI Growth Index;S&P Developed Ex-Asia-Pacific BMI Index;S&P DM Ex-Asia-Pacific BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Australia SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Australia Under USD3 Billion Index;S&P Developed Ex-Europe BMI Growth Health Care (Sector) Index;S&P Developed Ex-Australia SmallCap Growth Index;S&P Developed Ex-Switzerland BMI Index;S&P Developed Ex-Switzerland SmallCap Health Care (Sector) Index;S&P Developed Ex-Switzerland SmallCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-Switzerland Under USD1 Billion Index;S&P Developed Ex-Switzerland Under USD3 Billion Index;S&P Developed Ex-U.K. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Asia-Pacific SmallCap Growth Index;S&P Developed Ex-Asia-Pacific SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Index;S&P Developed Ex-Eurozone Under USD1.5 Billion Index;S&P Developed Ex-Japan BMI Index;S&P Developed Ex-Japan BMI Growth Health Care (Sector) Index;S&P Developed Ex-Japan BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific Under USD2 Billion Index;S&P Developed Ex-Australia BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Japan Under USD2 Billion Index;S&P Developed Ex-Switzerland BMI Health Care (Sector) Index;S&P Developed Ex-Switzerland SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Switzerland Under USD2 Billion Index;S&P Developed Ex-Europe SmallCap Index;S&P Developed Ex-Europe Under USD1 Billion Index;S&P Developed Ex-Europe Under USD1.5 Billion Index;S&P Developed Ex-Eurozone BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Eurozone Under USD1 Billion Index;S&P Developed Ex-Asia-Pacific Under USD1.2 Billion Index;S&P Developed Ex-Asia-Pacific Under USD3 Billion Index;S&P Developed Ex-Australia BMI Growth Index;S&P Developed Ex-Australia BMI Growth Health Care (Sector) Index;S&P Developed Ex-Australia BMI Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan BMI Growth Index;S&P DM Ex-U.S. & Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan Under USD1 Billion Index;S&P Developed Ex-Japan Under USD1.2 Billion Index;S&P Developed Ex-U.K. BMI Growth Health Care (Sector) Index;S&P Developed Ex-U.K. BMI Health Care (Sector) Index;S&P Developed Ex-U.K. Under USD1 Billion Index;S&P Developed Ex-U.K. Under USD1.2 Billion Index;S&P Developed Ex-U.S. & Japan SmallCap Growth Index;S&P Developed Ex-U.S. & Japan SmallCap Health Care (Sector) Index;S&P Developed Ex-U.S. & U.K. Under USD1.2 Billion Index;S&P Developed Ex-U.S. SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-U.S. Under USD3 Billion Index;S&P Developed Ex-U.S. & Japan Under USD1.2 Billion Index;S&P Developed Ex-U.S. & Japan Under USD1.5 Billion Index;S&P Developed Ex-U.S. & Japan Under USD2 Billion Index;S&P Developed Ex-U.S. & U.K. BMI Index;S&P Developed Ex-U.S. & U.K. BMI Growth Index;S&P Developed Ex-U.S. & U.K. SmallCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-U.S. & U.K. Under USD3 Billion Index;S&P Developed Ex-U.S. BMI Growth Health Care (Sector) Index;S&P Developed Under USD1.2 Billion Index;S&P Developed Under USD3 Billion Index;S&P Developed Ex-U.S. SmallCap Health Care (Sector) Index;S&P Developed SmallCap Index;S&P Developed Ex-Eurozone SmallCap Growth Index;S&P DM Ex-Eurozone SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan SmallCap Health Care (Sector) Index;S&P DM Ex-Japan SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Canada BMI Growth Health Care (Sector) Index;S&P Canada Under USD1.2 Billion Index;S&P Developed Ex-Europe BMI Index;S&P Developed Ex-U.K. SmallCap Index;S&P Developed Ex-U.K. Under USD1.5 Billion Index;S&P Developed Ex-U.S. & Japan BMI Index;S&P Developed Ex-U.S. & Japan BMI Growth Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan BMI Health Care (Sector) Index;S&P Developed Ex-U.K. BMI Growth Index;S&P Developed Ex-U.K. SmallCap Health Care (Sector) Index;S&P Developed BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific SmallCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-Europe SmallCap Growth Index;S&P Developed Ex-Europe Under USD1.2 Billion Index;S&P Developed Ex-Eurozone BMI Growth Health Care (Sector) Index;S&P Developed Ex-Eurozone Under USD1.2 Billion Index;S&P Developed Ex-Eurozone Under USD2 Billion Index;S&P Developed Ex-Eurozone Under USD3 Billion Index;S&P Developed Ex-U.S. & U.K. SmallCap Index;S&P Developed Ex-U.S. & U.K. Under USD1.5 Billion Index;S&P Developed Ex-U.S. BMI Growth Index;S&P Developed Ex-U.S. & U.K. BMI Growth Health Care (Sector) Index;S&P DM Ex-U.S. & U.K. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. & U.K. SmallCap Health Care (Sector) Index;S&P Developed Ex-U.S. & U.K. Under USD1 Billion Index;S&P Developed Ex-U.S. & U.K. Under USD2 Billion Index;S&P Developed Ex-U.S. BMI Index;S&P Developed Ex-U.S. BMI Health Care (Sector) Index;S&P Developed Ex-Australia SmallCap Health Care (Sector) Index;S&P Developed Ex-U.S. SmallCap Growth Index;S&P Global BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia BMI Health Care (Sector) Index;S&P Global Ex-Pan Asia SmallCap Pharmaceuticals, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Europe Under USD2 Billion Index;S&P Developed Ex-Europe Under USD3 Billion Index;S&P Developed Ex-Japan SmallCap Index;S&P Developed Ex-Switzerland BMI Growth Index;S&P Developed Ex-Switzerland BMI Growth Health Care (Sector) Index;S&P DM Ex-Switzerland BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. BMI Health Care (Sector) Index;S&P Developed Ex-U.S. Under USD1.2 Billion Index;S&P Developed Ex-U.S. Under USD1.5 Billion Index;S&P Developed Under USD1.5 Billion Index;S&P Developed Ex-Japan SmallCap Growth Index;S&P Developed Ex-Switzerland SmallCap Index;S&P Developed Ex-Switzerland SmallCap Growth Index;S&P Developed Ex-Switzerland Under USD1.5 Billion Index;S&P Developed Ex-U.K. SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.K. Under USD2 Billion Index;S&P Developed Ex-U.K. Under USD3 Billion Index;S&P Canada BMI Index;S&P Canada BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. & Japan SmallCap Index;S&P Developed Ex-U.S. & Japan Under USD1 Billion Index;S&P Developed Ex-U.S. & U.K. SmallCap Growth Index;S&P Canada Under USD1 Billion Index;S&P Developed BMI Growth Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific SmallCap Index;S&P Developed Ex-Asia-Pacific Under USD1 Billion Index;S&P Developed Ex-U.K. SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan SmallCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-U.S. & U.K. BMI Health Care (Sector) Index;S&P Developed Ex-Australia SmallCap Index;S&P Developed Ex-Europe BMI Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Health Care (Sector) Index;S&P Global Ex-Japan Under USD1.5 Billion Index;S&P Global Ex-Japan Under USD2 Billion Index;S&P Global Ex-Pan Asia BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. BMI Growth Index;S&P Developed Ex-Japan Under USD3 Billion Index;S&P Developed Ex-Switzerland Under USD1.2 Billion Index;S&P Developed Ex-U.K. BMI Index;S&P Global BMI Index;S&P Global Ex-Japan Under USD3 Billion Index;S&P Global Ex-Japan BMI Health Care (Sector) Index;S&P Global Ex-Pan Asia SmallCap Growth Index;S&P Global Ex-U.S. SmallCap Growth Index;S&P Global SmallCap Health Care (Sector) Index;S&P Developed Ex-U.S. SmallCap Index;S&P Developed Ex-U.S. Under USD2 Billion Index;S&P Developed Under USD2 Billion Index;S&P Global Ex-U.S. SmallCap Health Care (Sector) Index;S&P Global Ex-U.S. Under USD1.2 Billion Index;S&P Global Ex-U.S. Under USD3 Billion Index;S&P Global Under USD2 Billion Index;S&P Global Under USD3 Billion Index;S&P Global SmallCap Index;S&P Global SmallCap Growth Index;S&P North America SmallCap Index;S&P North America SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Japan SmallCap Index;S&P Global Ex-Japan Under USD1 Billion Index;S&P Global Ex-Japan Under USD1.2 Billion Index;S&P Global Ex-Pan Asia SmallCap Health Care (Sector) Index;S&P Global Ex-Pan Asia Under USD1 Billion Index;S&P Global Ex-Pan Asia Under USD1.5 Billion Index;S&P Global Ex-U.S. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. SmallCap Index;S&P Global Ex-U.S. Under USD2 Billion Index;S&P North America BMI Index;S&P Global SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia Under USD1.2 Billion Index;S&P Global Ex-Pan Asia Under USD2 Billion Index;S&P Global Ex-Pan Asia Under USD3 Billion Index;S&P Global Ex-U.S. BMI Index;S&P Global Ex-U.S. SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. Under USD1.5 Billion Index;S&P Global Under USD1 Billion Index;S&P Global Under USD1.5 Billion Index;S&P Developed Ex-U.S. & Japan Under USD3 Billion Index;S&P North America SmallCap Growth Health Care (Sector) Index;S&P North America BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P North America SmallCap Health Care (Sector) Index;S&P North America Under USD1.2 Billion Index;S&P North America Under USD1.5 Billion Index;S&P Developed Ex-U.S. & U.K. SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-U.S. Under USD1 Billion Index;S&P Developed SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Under USD1 Billion Index;S&P North America Under USD2 Billion Index;S&P North America Under USD3 Billion Index;S&P Global BMI Growth Index;S&P Global Ex-Japan BMI Growth Index;S&P Global Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Japan SmallCap Growth Index;S&P Global Ex-Pan Asia BMI Index;S&P Global Ex-Pan Asia BMI Growth Index;S&P Global Ex-U.S. Under USD1 Billion Index;S&P North America BMI Growth Index;S&P North America BMI Growth Health Care (Sector) Index;S&P North America BMI Health Care (Sector) Index;S&P Canada SmallCap Growth Health Care (Sector) Index;S&P Canada Under USD1.5 Billion Index;S&P Developed Ex-Asia-Pacific BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific SmallCap Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific Under USD1.5 Billion Index;S&P Developed Ex-Australia Under USD1.5 Billion Index;S&P Developed Ex-Australia Under USD2 Billion Index;S&P DM Ex-Europe SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Eurozone SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Japan BMI Growth Index;S&P Developed Ex-Japan Under USD1.5 Billion Index;S&P Developed Ex-U.K. SmallCap Growth Index;S&P Developed Ex-U.S. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed SmallCap Growth Index;S&P Developed SmallCap Growth Health Care (Sector) Index;S&P Developed SmallCap Health Care (Sector) Index;S&P Global BMI Health Care (Sector) Index;S&P Global Ex-Japan BMI Index;S&P Global Ex-Japan SmallCap Health Care (Sector) Index;S&P Global Ex-Japan SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia SmallCap Index;S&P Global Under USD1.2 Billion Index;S&P North America SmallCap Growth Index;S&P North America Under USD1 Billion Index;S&P Developed Ex-Japan BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Eurozone BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-U.S. & UK BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P North America BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-U.S. & Japan BMI Growth Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Canada BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Asia Pacific BMI Growth Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Switzerland BMI Growth Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-UK BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Australia BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-U.S. BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Israel BMI Growth Index;S&P Developed Ex-Israel BMI Growth Health Care (Sector) Index;S&P Developed Ex-Israel BMI Index;S&P Developed Ex-Israel BMI Health Care (Sector) Index;S&P Developed Ex-Israel BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Israel SmallCap Growth Index;S&P Developed Ex-Israel SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Israel SmallCap Index;S&P Developed Ex-Israel SmallCap Health Care (Sector) Index;S&P DM Ex-Israel SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Israel Under USD1 Billion Index;S&P Developed Ex-Israel Under USD1.2 Billion Index;S&P Developed Ex-Israel Under USD1.5 Billion Index;S&P Developed Ex-Israel Under USD2 Billion Index;S&P Developed Ex-Israel Under USD3 Billion Index;S&P Global Ex-Australia BMI Index;S&P Global Ex-Europe BMI Index;S&P Global Ex-United Kingdom BMI Index;S&P Developed Ex-Continental Europe BMI Index;S&P Developed Ex-Japan, Ex-South Korea BMI Index;S&P Developed BMI Ex-U.S. & Korea Index;S&P/TSX Smallcap Index - Health Care (Sector);S&P/TSX Smallcap Index - Pharmaceuticals & Biotechnology (Industry Group);S&P/TSX Smallcap Index - Pharmaceuticals (Industry);S&P/TSX Smallcap Index - Pharmaceuticals (Sub Industry);S&P DM Ex. Japan SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-Australia SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group;S&P DM Ex-Israel SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsect;S&P Developed Ex-U.S. & Japan SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsec;S&P Developed Ex-U.S. & U.K. SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsect;S&P Canada SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia-Pacific SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsec;S&P DM Ex-Europe SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-Eurozone SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Israel BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-U.S. SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-U.K. SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P North America SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Global Ex-China A BMI;S&P Global Ex-China A SmallCap;S&P Global Ex-U.S. & China A BMI;S&P Global Ex-U.S. & China A SmallCap;S&P Developed Ex-Korea BMI;S&P Developed Ex-U.S. & Korea SmallCap;S&P Developed Ex-Korea SmallCap;S&P Canada BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland BMI Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & Japan SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & UK BMI Grwth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia SmallCap Growth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Europe BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Israel SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia BMI Grwth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Europe SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P North America BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-UK BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-UK SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific BMI Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & Japan BMI Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. SmallCap Grwth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & UK SmallCap Growth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Korea BMI Growth


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Worldwide Rights to Impavido
As of February 27, 2018, Worldwide Rights to Impavido was acquired by Knight Therapeutics Inc.

United States and Canada
-
-
-
-
NeurAxon Inc.
NeurAxon Inc. discovers and develops pain therapeutics targeting neuronal nitric oxide synthase (nNOS). It focuses on the inhibition of nNOS, an enzyme that is involved in modulating pain and central nervous system neuronal sensitization. The company offers NXN-188, a dual-action small molecule incorporating nNOS inhibition and 5-HT agonism for the treatment of acute migraine. It also offers NXN-462, a product candidate for chronic migraine neuropathic pain; and other products for various indications, including inflammatory pain, severe pain, and migraine prophylaxis. The company was founded in 2004 and is based in Mississauga, Canada. As of January 1, 2015, NeurAxon Inc. operates as a subsidiary of Knight Therapeutics Inc..

United States and Canada
Pharmaceuticals
-
-
-
Orphan Canada Inc.
As of September 2, 2014, Orphan Canada Inc. operates as a subsidiary of Knight Therapeutics Inc.

United States and Canada
-
-
-
-
1178991 Canada Inc.

United States and Canada
-
-
-
-
Abir Therapeutics Ltd.
Abir Therapeutics Ltd. is headquartered in Israel. Abir Therapeutics Ltd. operates as a subsidiary of Knight Therapeutics Inc.

Africa / Middle East
-
-
-
-
Apicore LLC
Apicore LLC provides process research and development and API manufacturing services for the pharmaceutical industry worldwide. Its products and services range from APIs for the generic industry to custom synthesis for early phase pharmaceutical research and branded products. The company serves customers in the United States, Canada, Germany, France, Belgium, the Netherlands, Russia, the CIS region, and South East Asia. Apicore LLC was founded in 2003 and is headquartered in North Brunswick, New Jersey with an additional facility in Vadodara, India.

United States and Canada
Pharmaceuticals
11.00
-
-
Bloom Burton Healthcare Lending Trust
Bloom Burton Healthcare Lending Trust is based in Canada.

United States and Canada
Asset Management and Custody Banks
-
-
-

Investments as an LP
Bloom Burton Healthcare Lending Trust Ii, Forbion Capital Fund III, Forbion Capital Partners B.V., Genesys Capital Partners Inc., Genesys Ventures III LP, HarbourVest Canada Growth Fund, L.P., HarbourVest Partners, LLC, Stratigis Capital Advisors Inc., Teralys Capital, Teralys Capital Innovation Fund 2014 LP, TVM Capital GmbH, TVM Life Science Innovation I


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jul-12-2023
-
Buyback
Target
Knight Therapeutics Inc. (TSX:GUD)


-
Jul-12-2022
-
Buyback
Target
Knight Therapeutics Inc. (TSX:GUD)


30.67
Jul-12-2021
-
Buyback
Target
Knight Therapeutics Inc. (TSX:GUD)


31.20
Dec-9-2020
-
Shelf Registration
Target
Knight Therapeutics Inc. (TSX:GUD)


268.50
Jul-10-2020
-
Buyback
Target
Knight Therapeutics Inc. (TSX:GUD)


39.09
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-10-2023
Product-Related Announcements
United Medical Ltd. Announces Regulatory Submission of Pemigatinib in Brazil
Aug-10-2023
Earnings Calls
Knight Therapeutics Inc., Q2 2023 Earnings Call, Aug 10, 2023
Aug-10-2023
Corporate Guidance - New/Confirmed
Knight Therapeutics Inc. Updates Earnings Guidance for the Fiscal Year 2023
Aug-10-2023
Buyback Tranche Update
Tranche Update on Knight Therapeutics Inc. (TSX:GUD)'s Equity Buyback Plan announced on July 12, 2022.
Jul-13-2023
Buyback Transaction Closings
Knight Therapeutics Inc.'s Equity Buyback announced on July 12, 2022, has expired with 7,785,625 shares, representing 6.95% for CAD 40.25 million.

Competitors
Abbott Laboratories (NYSE:ABT), Adium Pharma S.A., Bausch Health Companies Inc. (NYSE:BHC), EMS S.A., Eurofarma Laboratórios S.A., Gador S.A., HLS Therapeutics Inc. (TSX:HLS), Hypera S.A. (BOVESPA:HYPE3), Laboratorios Bago De Bolivia Sa, Laboratorios Roemmers S.A.I.C.F., Pint Pharma GmbH, Searchlight Pharma Inc., Valeo Pharma Inc. (TSX:VPH)

M&A Advisors
Brigard & Urrutia S.A.S., Davies Ward Phillips & Vineberg LLP, Estudio Beccar Varela, Ferrere Abogados, Pinheiro Neto Advogados, RBC Capital Markets Inc.


Advisors
Most Recent Auditor
Ernst & Young LLP
M&A Advisors
Brigard & Urrutia S.A.S., Davies Ward Phillips & Vineberg LLP, Estudio Beccar Varela, Ferrere Abogados, Pinheiro Neto Advogados, RBC Capital Markets Inc.
Private Placement Advisors
Bloom Burton & Co. Inc., Cormark Securities Inc., Haywood Securities Inc., RF Securities Clearing LP
Public Offering Advisors
Davies Ward Phillips & Vineberg LLP, Ernst & Young LLP (Canada)


Most Recent Auditor
Ernst & Young LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Marktfeld
Paraskevopoulos, Michail
Oct 10, 2023 08:16 AM
GUD
Knight Therapeutics Inc (GUD.CA): Investor Targeting - October 2023
Reports
5
The Economy Matters

Oct 09, 2023 01:19 AM
GUD
The Economy Matters
Reports
8
CFRA Equity Research

Oct 08, 2023 05:49 AM
GUD
Knight Therapeutics Inc.
Reports
9
S&P Global Compustat

Oct 05, 2023 03:54 AM
GUD
Knight Therapeutics Inc 2023_10_05
Reports
15
ValuEngine, Inc.

Oct 02, 2023 06:15 AM
GUD
ValuEngine - Toronto Quantitative Stock Report for GUD
Reports
5
Jefferson Research & Management

Sep 15, 2023 01:04 PM
GUD
Jefferson Financial - Knight Therapeutics Inc.
Reports
11
MarketLine

Sep 14, 2023 06:01 AM
GUD
Knight Therapeutics Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
181
GlobalData

Sep 12, 2023 04:03 AM
GUD
Knight Therapeutics Inc (GUD.TSE) - Financial Analysis Review
Reports
245
Jefferson Research & Management

Sep 08, 2023 01:06 PM
GUD
Jefferson Financial - Knight Therapeutics Inc.
Reports
11
S&P Global Compustat

Sep 07, 2023 03:46 AM
GUD
Knight Therapeutics Inc 2023_09_07
Reports
15


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Goodman B.A., BA, L.L.B., LLB, M.B.A., MBA, Jonathan Ross

22,541,475

21.19

104.6

Sep-22-2023


G2S2 Capital Inc.

12,236,700

11.50

56.8

Sep-27-2023


Medici Strategic Portfolio Management Inc

11,506,844

10.82

53.4

Apr-30-2023


Industrial Alliance Investment Management Inc.

2,936,869

2.76

13.6

Mar-31-2023


Dimensional Fund Advisors LP

2,479,943

2.33

11.5

Sep-30-2023


QV Investors Inc.

2,028,806

1.91

9.4

Mar-31-2023


FMR LLC

1,772,213

1.67

8.2

Mar-31-2023


Desjardins Global Asset Management Inc.

415,756

0.39

1.9

Mar-31-2023


Bessemer Investment Management LLC

411,025

0.39

1.9

Jul-31-2023


North Growth Management Ltd.

397,000

0.37

1.8

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Medici Strategic Portfolio Management Inc
11,506,844
11,506,844
G2S2 Capital Inc.
12,236,700
230,300
Goodman B.A., BA, L.L.B., LLB, M.B.A., MBA, Jonathan Ross
22,541,475
26,489
Artisan Partners Limited Partnership
125,000
21,400
Sakhia BCom, CA, CPA, MBA, Samira 
193,266
3,331

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Maxam Capital Management Ltd.
185,000
(200,000)
Manulife Asset Management
18,800
(193,730)
Connor, Clark & Lunn Investment Management Ltd.
(3,000)
(156,600)
AGF Management Limited
270,900
(151,100)
Dimensional Fund Advisors LP
2,479,943
(122,926)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
60P Family Products (Future), 60P001 (Glucosidase Inhibitor) (Future), 60P002 (PAFR Antagonist) (Future), 60P0034 (Future), 60P004 (Synthetic Retinoid) (Future), Abraxane, ADXS-HER2 (Future), ADXS-PSA (Future), Akynzeo, Aloxi, AmBisome, Arakoda, ATB-340 (Future), ATB-346 (Future), ATB-352 (Future), ATryn, Axalimogene Filolisbac (Future), AzaSite, Bijuva, Blood Factor Products (Future), BMP-7 (Future), BMP-7 (OA) (Future), Cresemba, Dermo-Cosmetic Products (Future), Diagnostic and Prognostic Products (Future), Distribution of Advaxis Family Products (Future), Distribution of Antibe Family Products (Future), Distribution of Burinex, Distribution of Flat Tummy Tea, Distribution of Hand MD (Future), Distribution of Migralex, Distribution of Movantik, Distribution of Mytesi (Future), Distribution of Netildex, Distribution of RHY/Vavelta, Distribution of Tenapanor (Future), Distribution of Triumvira Family Products (Future), Dolufevir, Exelon, Fibridoner, FLEXISEQ (Future), FOCUSfactor, Fostamatinib, Halaven, Ibsrela, Iluvien, Impavido, Imvexxy, Karfib, Laboratoire Dr. Renaud (Future), Ladevina, Lenvima, Leprid, Licensing of Impavido, Nerlynx, Neuragen, NeurAxon Family Products (Future), NXN-188 9(nNOS/5HT) (Future), NXN-462(nNOS) (Future), NXN-677 (nNOS/iNOS) (Future), Palbocil, Pemigatinib, Photofrin, Premiology (Future), Pro-Derm (Future), Probuphine, Rembre, Salofalk, SEQuaderma (Future), Synergy Family Products, Tafasitamab, Tobradosa Haler, Toliscrin 1-2, Toliscrin DPI, Trelstar, Tropical Products (Future), TULSA-PRO (Future), UrgentRx (Future), Ursofalk, VEWS (Future), Vidaza, Zyvalix


Upcoming Events
Date/Time
Type
Nov-07-2023
Company Conference Presentations
Nov-07-2023
Conferences
Nov-10-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Language
Size
Aug-14-2023
Dec-31-2022
Knight Therapeutics Inc. (TSX:GUD)
Company Website
Annual Report
English
12 MB
Aug-10-2023
Jun-30-2023
Knight Therapeutics Inc. (TSX:GUD)
SEDAR
Interim Financial Statements
English
269 KB
Aug-10-2023
-
Knight Therapeutics Inc. (TSX:GUD)
SEDAR
News Releases
French
480 KB
Aug-10-2023
-
Knight Therapeutics Inc. (TSX:GUD)
SEDAR
News Releases
English
298 KB
Aug-10-2023
Jun-30-2023
Knight Therapeutics Inc. (TSX:GUD)
Company Website
Interim Report
English
835 KB
Jul-12-2023
-
Knight Therapeutics Inc. (TSX:GUD)
SEDAR
News Releases
French
86 KB
Jul-12-2023
-
Knight Therapeutics Inc. (TSX:GUD)
SEDAR
News Releases
English
25 KB
May-11-2023
Mar-31-2023
Knight Therapeutics Inc. (TSX:GUD)
SEDAR
Interim Financial Statements
English
1 MB
May-11-2023
-
Knight Therapeutics Inc. (TSX:GUD)
SEDAR
News Releases
French
444 KB
May-11-2023
-
Knight Therapeutics Inc. (TSX:GUD)
SEDAR
News Releases
English
242 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
G2S2 Capital Inc.
Sep-26-2023 - Sep-27-2023
Common Shares
82,900
363,689
Open Market Acquisition
0.68
Multiple
-
Sep-26-2023
Common Shares
29,900
131,591
Open Market Acquisition
-
Exchange Announcement
-
Sep-27-2023
Common Shares
3,000
13,142
Open Market Acquisition
-
Exchange Announcement
-
Sep-26-2023
Common Shares
50,000
218,955
Open Market Acquisition
-
Exchange Announcement
Goodman B.A., BA, L.L.B., LLB, M.B.A., MBA, Jonathan Ross (Executive Chairman)
Sep-22-2023
Common Shares
25,000
111,633
Open Market Acquisition
0.11
Multiple
G2S2 Capital Inc.
Sep-20-2023 - Sep-25-2023
Common Shares
43,300
191,872
Open Market Acquisition
0.36
Multiple
-
Sep-20-2023
Common Shares
13,200
58,372
Open Market Acquisition
-
Exchange Announcement
-
Sep-21-2023
Common Shares
21,500
95,301
Open Market Acquisition
-
Exchange Announcement
-
Sep-22-2023
Common Shares
2,800
12,432
Open Market Acquisition
-
Exchange Announcement
-
Sep-25-2023
Common Shares
5,800
25,766
Open Market Acquisition
-
Exchange Announcement
G2S2 Capital Inc.
Sep-19-2023
Common Shares
18,000
79,725
Open Market Acquisition
0.15
Multiple
Sakhia BCom, CA, CPA, MBA, Samira  (President, CEO & Director)
Sep-15-2023
Common Shares
3,331
14,814
Acquisition Under Employee Benefit Plan
1.75
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Goodman, Jonathan Ross
Executive Chairman
514-484-4483
514-481-4116

Sakhia, Samira 
President, CEO & Director
514.484.4483x122
(514) 481-4116

Lande, Robert N.
Independent Director
514-484-4483
514-481-4116
rlande@fxcm.com
Tremblay, Michael J.
Independent Director
514-484-4483
514-481-4116

Gale, James Charles
Independent Lead Director
(212) 872-3900
(212) 826-3440
james.gale@signethp.com
Murray, Janice 
Independent Director
514-484-4483
514-481-4116

Sujoy, Nicolas 
Independent Director
5411-4853-5700
514-481-4116
Nicolas@claracapital.com.ar
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Goodman, Jonathan Ross
Executive Chairman
514-484-4483
514-481-4116

Sakhia, Samira 
President, CEO & Director
514.484.4483x122
(514) 481-4116

Utchanah, Arvind 
Chief Financial Officer
+598 2626 2344
514.481.4116

Bosano, Leopoldo 
Vice-President of Manufacturing & Operations
514-484-4483
514-481-4116

Percario, Monica 
Global Vice President of Scientific Affairs
514-484-4483
514-481-4116

Dias, Henrique 
Global Director of Marketing
514-484-4483
514-481-4116

Emblem, Susan Caroline
Global Vice President of Human Resources
514-484-4483
514-481-4116

Khouri, Amal 
Chief Business Officer
514-484-4483
514-481-4116

Martens, Jeff 
Global Vice President of Commercial
514-484-4483
514-481-4116

Saverio, Stephani 
Vice President of Business Development
514-484-4483
514-481-4116

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
